You are here: Industry Insights > Pfizer

News List

Merck and Pfizer's joint skin cancer drug gets EU approval pharmafile
September 22, 2017
Merck KGaA and Pfizer have announced that European authorisation of their jointly developed drug Bavencio (avelumab) as a monotherapy in the treatment of metastatic Merkel cell carcinoma (mMCC), a rare and aggressive skin cancer.
Pfizer leads Big Pharma's emerging markets growth as GlaxoSmithKline, Eli Lilly lag fiercepharma
September 21, 2017
Big Pharma’s businesses in emerging markets grew 6.1% sequentially in the second quarter, the fastest in more than two years, according to a recent tally by Bernstein analysts, but some grew much faster than others.
Pfizer goes to Court to allow competition for biologics and expand options for patients worldpharmanews
September 21, 2017
To ensure patients and providers have access to important, lower cost biosimilar medicines, Pfizer (NYSE:PFE) has filed suit in the U.S. District Court for the Eastern District of Pennsylvania against Johnson & Johnson (J&J).
Pfizer, Astellas prostate cancer drug promising in late-stage trial expressbpd
September 18, 2017
Pfizer and Astellas jointly sell Xtandi in the US, while Astellas owns the rights to develop and sell Xtandi outside the US
Pfizer receives prostate cancer drug boost with trial results pharmafile
September 18, 2017
Pfizer, and its partner Astellas Pharma, received a major boost to its plans for prostate cancer treatment, Xtandi, by announcing it has received positive data for treating the condition at an early stage.
FDA slams Pfizer unit that made EpiPens that failed during fatal emergencies fiercepharma
September 08, 2017
Mylan last spring recalled tens of thousands EpiPen injectors that had been manufactured by a Pfizer unit that were potentially faulty.
Pfizer’s drug back on the market after proving safety pharmafile
September 06, 2017
Back in 2000, Pfizer had a drug that was granted accelerated approval for the treatment of acute myeloid leukaemia (AML) and was continued to be used for 10 years.
Withdrawn 7 years ago, Pfizer’s Mylotarg is back to market pharmatimes
September 05, 2017
US regulators have approved Pfizer’s Mylotarg as a treatment for AML after the drug was with voluntarily withdrawn from the market 7 years ago.
Pfizer, Avillion file for Bosulif expansion pharmatimes
August 31, 2017
Pfizer and Avillion have filed applications on both sides of the Atlantic seeking to expand the treatment scope of chronic myeloid leukaemia therapy Bosulif.
Pfizer's hunt for new Manhattan HQ lands on snazzy Spiral skyscraper: report fiercepharma
August 28, 2017
Selling Pfizer's old headquarters just got a lot more attractive, according to the Post, which said recent rezoning will allow a much taller building to rise in its place, making the site more valuable.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 83 84 Next page